Savara Inc(SVRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SVRA Savara Inc

Pre-Mkt 10-27 06:17:58 EDT

4.52

+0.30

+7.11%

High4.54	Low4.22	Vol3.45M
Open4.34	D1 Closing4.22	Amplitude7.68%
Mkt Cap925.05M	Tradable Cap895.86M	Total Shares204.66M
T/O15.11M	T/O Rate1.74%	Tradable Shares198.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SVRA","market":"US","secType":"STK","nameCN":"Savara Inc","latestPrice":4.52,"timestamp":1793044800000,"preClose":4.22,"halted":0,"volume":3449003,"delay":0,"changeRate":0.07109004739336489,"floatShares":198198210,"shares":204657499,"eps":-0.578152,"marketStatus":"Pre-Mkt","change":0.3,"latestTime":"10-27 06:17:58 EDT","open":4.335,"high":4.54,"low":4.216,"amount":15114558.948893998,"amplitude":0.076777,"askPrice":4.99,"askSize":100,"bidPrice":4.5,"bidSize":20,"shortable":3,"etf":0,"ttmEps":-0.578152,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1793107800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":4.52,"postHourTrading":{"tag":"盘后","latestPrice":4.54,"preClose":4.52,"latestTime":"19:42 EDT","volume":64992,"amount":294867.3815,"timestamp":1793058126947,"change":0.02,"changeRate":0.004425,"amplitude":0.028761},"volumeRatio":1.2669627392847091,"impliedVol":1.6645,"impliedVolPercentile":0.612},"requestUrl":"/m/hq/s/SVRA/wiki","defaultTab":"wiki","newsList":[{"id":"2677284923","title":"Mastek Ltd Says Sept-Quarter Consol Net Profit 1.06 Billion Rupees","url":"https://stock-news.laohu8.com/highlight/detail?id=2677284923","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677284923?lang=en_us&edition=fundamental","pubTime":"2026-10-23 18:24","pubTimestamp":1792751066,"startTime":"0","endTime":"0","summary":"Oct 23 (Reuters) - Mastek Limited::*SEPT-QUARTER CONSOL NET PROFIT 1.06 BILLION RUPEES*SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 10.19 BILLION RUPEES((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 23-OCT-202610:13:54 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261023:nRSD7VjTz2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677605279","title":"Savara’s Molgramostim Improves Gas Transfer in Exploratory aPAP Trial Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2677605279","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677605279?lang=en_us&edition=fundamental","pubTime":"2026-10-22 01:10","pubTimestamp":1792602628,"startTime":"0","endTime":"0","summary":"Savara’s Molgramostim Improves Gas Transfer in Exploratory aPAP Trial AnalysisSavara presented molgramostim results in autoimmune pulmonary alveolar proteinosis patients with mild diffusion impairment","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261021:nNDLJMf42:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675795807","title":"Savara to Present New Impala Trial Analysis of Molgramostim in aPAP at CHEST 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2675795807","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675795807?lang=en_us&edition=fundamental","pubTime":"2026-10-13 04:06","pubTimestamp":1791835569,"startTime":"0","endTime":"0","summary":"Savara to present new IMPALA trial analysis of molgramostim in aPAP at CHEST 2026Savara flagged new analyses of molgramostim from its IMPALA and IMPALA-2 trials in autoimmune pulmonary alveolar protei","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nNDL7TqkLj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673909941","title":"Savara Inc. : JP Morgan Initiates Coverage with Overweight Rating; Target Price $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2673909941","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673909941?lang=en_us&edition=fundamental","pubTime":"2026-10-07 17:03","pubTimestamp":1791363828,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nFWN45T0QQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673888055","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2673888055","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673888055?lang=en_us&edition=fundamental","pubTime":"2026-10-06 19:12","pubTimestamp":1791285178,"startTime":"0","endTime":"0","summary":"Option Care Health  shares were up 19% pre-bell Tuesday, a day after Financial Times reported the company is in advanced talks to be acquired by McKesson  and private equity firm Clayton Dubilier & Rice in a deal valuing the company at over $5 billion, including debt.Apogee Enterprises  stock was up 19% after the company reported higher fiscal Q2 adjusted earnings and sales.Robo.ai  shares were 11% higher after the company reported September revenue and provided fiscal 2026 sales guidance.InTest  stock was up 9% after the company provided its outlook for Q3 and fiscal 2026.Savara  shares were 6% higher following a 0.6% decline in Monday's session.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0432979614.USD","LU1366192091.USD","LU1061106388.HKD","APOG","LU0689626769.HKD","BK4099","OPCH","LU0122379950.USD","LU0203345920.USD","LU1934455277.USD","BK4588","LU2468319806.SGD","LU0742534661.SGD","LU1934455863.HKD","LU0342679015.USD","LU1814569148.SGD","LU1506573853.SGD","INTT","LU0114720955.EUR","LU1983260115.SGD","BK4585","LU0048573561.USD","LU0314106906.USD","LU0868494708.USD","LU1037948541.HKD","MCK","LU0203347892.USD","BK4533","LU2112291526.USD","AIIO","LU1057294990.SGD","LU2089984988.USD","BK4139","BK4196","LU0942090050.USD","LU0106261612.USD","LU0861579265.USD","BK4147","LU0882574055.USD","LU1037948897.HKD","SVRA","LU0251131958.USD","LU0124676726.USD","BK4086","LU0965509283.SGD","LU1023059063.AUD","LU0251142724.SGD","LU0965509010.AUD","LU0868494617.USD","LU0965509101.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662715415","title":"Piper Sandler Sticks to Their Buy Rating for Savara (SVRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662715415","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662715415?lang=en_us&edition=fundamental","pubTime":"2026-08-26 19:35","pubTimestamp":1787744141,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Savara today and set a price target of $16.00. According to TipRanks, Rahimi is a 5...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-savara-svra-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-savara-svra-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662206573","title":"Savara  announces presentations of Results from Phase 3 trial of Molgramostim","url":"https://stock-news.laohu8.com/highlight/detail?id=2662206573","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662206573?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:10","pubTimestamp":1787602218,"startTime":"0","endTime":"0","summary":"Savara (SVRA) announced the acceptance of one oral presentation and two poster presentations on data from the Phase 3 IMPALA-2 clinical trial at th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/savara-announces-presentations-of-results-from-phase-3-trial-of-molgramostim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/savara-announces-presentations-of-results-from-phase-3-trial-of-molgramostim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NVIB","MEDX","PSIL","SVRA","BBC","IDNA","GDOC","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662866206","title":"Savara to Present Phase 3 Impala-2 Molgramostim Data in Autoimmune Pulmonary Alveolar Proteinosis at ERS 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662866206","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662866206?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:06","pubTimestamp":1787601962,"startTime":"0","endTime":"0","summary":"Savara to present Phase 3 IMPALA-2 molgramostim data in autoimmune pulmonary alveolar proteinosis at ERS 2026Savara flagged new Phase 3 IMPALA-2 data for molgramostim in autoimmune pulmonary alveolar ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL9Sx06R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662205046","title":"Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (Apap) at the European Respiratory Society (Ers) Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2662205046","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662205046?lang=en_us&edition=fundamental","pubTime":"2026-08-25 04:05","pubTimestamp":1787601900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA7PWJJ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661234716","title":"Savara Grants New Hires Options for 74,500 Shares at $5.37, RSUs for 64,500 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2661234716","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661234716?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:05","pubTimestamp":1787256320,"startTime":"0","endTime":"0","summary":"Savara grants new hires options for 74,500 shares at $5.37, RSUs for 64,500 sharesSavara granted inducement equity awards on Aug. 17, 2026 to eight newly hired employees.Awards include stock options f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDLcZbQC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658794531","title":"Savara Merilis Presentasi Korporasi Tentang Penyakit Paru Langka Autoimmune PAP Dan Kandidat Terapi Inhalasi Molbreevi","url":"https://stock-news.laohu8.com/highlight/detail?id=2658794531","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658794531?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:40","pubTimestamp":1786480802,"startTime":"0","endTime":"0","summary":"Savara merilis presentasi korporasi tentang penyakit paru langka autoimmune PAP dan kandidat terapi inhalasi MOLBREEVISavara Inc. menyoroti kandidat utama MOLBREEVI (molgramostim inhalation solution) ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL8DcjMY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658842945","title":"Savara Q2 EPS $(0.16) Misses $(0.14) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658842945","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658842945?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:36","pubTimestamp":1786480619,"startTime":"0","endTime":"0","summary":"Savara (NASDAQ:SVRA) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 14.29 percent decrease over losses of $(0.14) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61128259/savara-q2-eps-0-16-misses-0-14-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Savara Q2 EPS $(0.16) Misses $(0.14) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658943230","title":"Savara Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658943230","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658943230?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:29","pubTimestamp":1786480184,"startTime":"0","endTime":"0","summary":"Savara Inc. reports results for the quarter ended June 30 - Earnings SummarySavara Inc.SVRA.OQreported a quarterly adjusted loss of 16 cents per share for the quarter ended June 30, lower than the sam","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL8N44823B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658801943","title":"Savara Q2 Loss Widens as Operating Expenses Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2658801943","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658801943?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:13","pubTimestamp":1786479231,"startTime":"0","endTime":"0","summary":"Savara Q2 loss widens as operating expenses riseOverviewUS rare respiratory drug developer's Q2 net loss widened from prior yearOperating expenses rose, driven by higher personnel costs and commercial","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL1N4480YW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242652126.USD","LU0868494617.USD","LU1989771016.USD","SVRA","LU0061475181.USD","LU0882574055.USD","LU1670711123.USD","LU1093756168.USD","LU2125154778.USD","IE00BFTCPJ56.SGD","IHE","LU2133065610.SGD","FTXH","BK4532","LU0985481810.HKD","LU1868836757.USD","NGNE","LU0432979614.USD","BK4581","LU1585245621.USD","LU0225771236.USD","IE0002141913.USD","LU1883839398.USD","LU1868837136.USD","LU2242646821.SGD","LU0321505439.SGD","LU1670710661.SGD","BK4559","LU0267386448.USD","LU2596442595.SGD","LU1670711040.USD","LU1868836591.USD","LU1868837300.USD","TARA","BK4588","LU0306806265.USD","IE00BJJMRZ35.SGD","LU1323610961.USD","LU1093756325.SGD","LU1261432733.SGD","BK4585","IE0009355771.USD","IE00BFXG1179.USD","LU1670710588.SGD","LU0114720955.EUR","LU1868836914.USD","LU2360032135.SGD","BMY","LU0237698245.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948298","title":"Savara Rugi Bersih Q2 FY26 Melebar 32,3% Ke USD 40,2 Juta","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948298","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948298?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:08","pubTimestamp":1786478900,"startTime":"0","endTime":"0","summary":"Savara rugi bersih Q2 FY26 melebar 32,3% ke USD 40,2 jutaSavara Inc. mencatat rugi bersih kuartal II 2026 melebar menjadi USD 40,2 juta, setara rugi per saham USD 0,16.Beban R&D naik 5,8% menjadi USD ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL7PNStd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948117","title":"Savara Q2 Net Income USD -40.228 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948117","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948117?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:06","pubTimestamp":1786478761,"startTime":"0","endTime":"0","summary":"BRIEF-Savara Q2 Net Income USD -40.228 MillionAug 11 (Reuters) - Savara Q2 operating expenses USD 40.965 million.Q2 income from operations USD -40.965 millionQ2 EPS USD -0.16","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXD657ZD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945640","title":"Savara - European and Australian Patent Offices Grant Molbreevi Patents Until March 2041","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945640","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945640?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:05","pubTimestamp":1786478701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXD657ZD:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658456589","title":"Savara - Molbreevi MAAS Under Review by Ema and U.k's Mhra; Decisions Expected Q1 2027 and Q4 2026, Respectively","url":"https://stock-news.laohu8.com/highlight/detail?id=2658456589","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658456589?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:05","pubTimestamp":1786478701,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXD657ZD:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655870836","title":"Savara announces EPO granted a patent covering formulation of Molbreevi","url":"https://stock-news.laohu8.com/highlight/detail?id=2655870836","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655870836?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:38","pubTimestamp":1785415135,"startTime":"0","endTime":"0","summary":"Savara (SVRA) announced that the European Patent Office, EPO, has granted a patent covering the liquid formulation of Molbreevi, an orally inhaled ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/savara-announces-epo-granted-a-patent-covering-formulation-of-molbreevi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/savara-announces-epo-granted-a-patent-covering-formulation-of-molbreevi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPV","BK4139","SVRA","USRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655872497","title":"Savara Says Europe, Australia Grant Molbreevi Liquid Formulation Patents Through 2041","url":"https://stock-news.laohu8.com/highlight/detail?id=2655872497","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655872497?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:11","pubTimestamp":1785413512,"startTime":"0","endTime":"0","summary":"Savara says Europe, Australia grant MOLBREEVI liquid formulation patents through 2041Savara secured granted patents in Europe and Australia covering the liquid formulation of MOLBREEVI, extending prot","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL1VH4r0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SVRA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.savarapharma.com","stockEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":-0.096},{"period":"3month","weight":-0.152},{"period":"6month","weight":-0.068},{"period":"1year","weight":0.0367},{"period":"ytd","weight":-0.2504}],"compareEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":-0.0078},{"period":"3month","weight":0.0331},{"period":"6month","weight":0.0756},{"period":"1year","weight":0.1301},{"period":"ytd","weight":0.1224}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Austin, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":0.103891},{"month":2,"riseRate":0.307692,"avgChangeRate":-0.038506},{"month":3,"riseRate":0.384615,"avgChangeRate":-0.017596},{"month":4,"riseRate":0.571429,"avgChangeRate":0.029792},{"month":5,"riseRate":0.642857,"avgChangeRate":0.021325},{"month":6,"riseRate":0.5,"avgChangeRate":-0.018175},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.03016},{"month":8,"riseRate":0.5,"avgChangeRate":0.01418},{"month":9,"riseRate":0.5,"avgChangeRate":0.007273},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.135855},{"month":11,"riseRate":0.538462,"avgChangeRate":0.131385},{"month":12,"riseRate":0.538462,"avgChangeRate":0.21983}],"exchange":"NASDAQ","name":"Savara Inc","nameEN":"Savara Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Savara Inc(SVRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Savara Inc(SVRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Savara Inc,SVRA,Savara Inc股票,Savara Inc股票老虎,Savara Inc股票老虎国际,Savara Inc行情,Savara Inc股票行情,Savara Inc股价,Savara Inc股市,Savara Inc股票价格,Savara Inc股票交易,Savara Inc股票购买,Savara Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Savara Inc(SVRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Savara Inc(SVRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}